June 17, 2025
RAD 2025: Peter Lio, MD, discussed the benefits of disease-specific meetings, the evolving AD landscape, and why continuity across sessions enhances clinician education.
June 17, 2025
The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026.
June 17, 2025
EAACI 2025. New data revealed the effectiveness of rademikibart in improving lung function and reducing asthma exacerbations in patients with eosinophilic-driven type 2 asthma.
June 17, 2025
Using FMT over standard-of-care therapy may significantly reduce antibiotic use and well-known harms, including antibiotic resistance, study authors noted.
June 17, 2025
For individuals with T2D, findings are more than numeric; a 5-mm Hg reduction in SBP reduces stroke risk by 14%, CV events by 6%, and heart failure by 8%, authors wrote.
June 16, 2025
Among 2000 US adults, a new survey found consumers prioritize trust and recommendations over brand loyalty in health tracking devices, prizing accuracy and reliability.
June 16, 2025
AUD affects 15 million Americans, with men nearly 2 times more vulnerable to the disease vs women. Are you tracking signs and symptoms in your patients?
June 16, 2025
Solriamfetol's significant cognitive benefits may be the result of mechanisms operating independently of its wake-promoting effects, study authors suggest.
June 16, 2025
RAD 2025: Glick spoke to Patient Care about the similarities between TSW and a flare of atopic dermatitis as well as specific signs now being identified d as characteristic.
June 16, 2025
The phase 4 EVEREST study showed statistically significant improvements in polyp size reduction and smell identification ability as early as 4 weeks of treatment.